Clinical Trials · NCT02906163
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
- Phase
- Phase 1/Phase 2
- Recruitment status
- Unknown
- Sponsor
- SciClone Pharmaceuticals
- Enrollment
- 188
- Start date
- Oct 2016
- Locations
- 5 sites, Italy
- Primary endpoint
- Number of treatment-related adverse events